NEW YORK (GenomeWeb) – Exact Sciences late Sunday said that it expects to report fourth quarter revenues of $86.9 million to $87.9 million, an increase of about 148 percent from Q4 2016.

The firm said it completed approximately 176,000 Cologuard colorectal cancer screening tests, 115 percent more than the year before. Nearly 11,000 health care providers ordered Cologuard for the first time during Q4.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.